Consolidated revenue grew 30.14% YoY to INR 96.47 Cr. Molecular Diagnostics (Standalone Non-COVID) revenue grew 37.66% YoY to INR 78.13 Cr, while Agrochemicals revenue declined 10....

Standalone revenue grew by 29.32% to INR 129.16 Cr in FY25, while H1 FY26 consolidated revenue reached INR 137.49 Cr, a 23.38% YoY increase. The diagnostic segment is a primary dri...

Vinchurkar Diagnostics (Target Entity) revenue grew 8.18% in FY24 (INR 444.53 Lakhs) and 0.2% in FY25 (INR 445.44 Lakhs). Porteus Medical LLP and Primacare Diagnostic LLP contribut...

Not disclosed in available documents.

While absolute revenue figures are not disclosed, the Net Capital Turnover Ratio improved by 43.12% (from 5.96 to 8.53), indicating significantly higher revenue generation efficien...

Not disclosed in available documents. The company has not provided specific percentage growth for its imaging or pathology segments.